



(51) International Patent Classification:
C12N 15/11 (2006.01)

(21) International Application Number:
PCT/US2021/026732

(22) International Filing Date:
09 April 2021 (09.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/007,803 09 April 2020 (09.04.2020) US
63/007,797 09 April 2020 (09.04.2020) US
63/045,032 26 June 2020 (26.06.2020) US
63/045,033 26 June 2020 (26.06.2020) US
63/136,087 11 January 2021 (11.01.2021) US

(71) Applicant: **VERVE THERAPEUTICS, INC.** [US/US];
500 Technology Square, Suite 901, Cambridge, Massachu-
setts 02139 (US).

(72) Inventors: **CHADWICK, Alexandra**; 500 Technology
Square, Suite 901, Cambridge, Massachusetts 02139 (US).

RAJEEV, Kallanthottathil G.; 500 Technology Square,
Suite 901, Cambridge, Massachusetts 02139 (US). **RO-
HDE, Ellen**; 500 Technology Square, Suite 901, Cam-
bridge, Massachusetts 02139 (US). **CHENG, Christopher**;
500 Technology Square, Suite 901, Cambridge, Massa-
chusetts 02139 (US). **REISS, Caroline**; 500 Technology
Square, Suite 901, Cambridge, Massachusetts 02139 (US).

(74) Agent: **UM, Moonkyoung**; Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: BASE EDITING OF PCSK9 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE




FIG. 34

(57) Abstract: Provided herein are compositions for gene modification or editing and methods of using same to treat or prevent certain conditions. Specific compositions and methods capable of safely and effectively editing gene targets expressed in the liver to durably lower LDL-C thereby treating a leading cause of cardiovascular disease are disclosed.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*